An observational study in Hair Loss, sponsored by National Skin Centre. Not yet recruiting. Open to male participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by National Skin Centre · Observational
This study is to evaluate differences in the gut and follicle/scalp microbiome signature in AGA compared to a non-AGA population. Also, to investigate differences in inflammation and other biomarkers in AGA compared to non-AGA population at baseline and after a successful treatment
511 studies on the registry are indexed under Alopecia; 128 are open to participants now.
This study's planned enrollment of 66 is below the median of 95 across 52 observational studies indexed under Alopecia.
Browse Alopecia studies →National Skin Centre is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
AGA volunteers will be referred by clinicians from National Skin Centre Healthy volunteers will be recruited by recruitment posters at National Skin Centre
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Volunteers in the healthy control panel must satisfy the following criteria:
Volunteers in the AGA panel must satisfy the following criteria:
Exclusion Criteria:
Non-inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
With no hair loss
With hairloss
Norwoord-Hamiton scale hairloss severity
Scale from 1 (no hair loss) to 7 (severe hair loss)
Time frame: 6 months
Change in hair density
Change from baseline in hair density at the vertex, crown and occipital zones Unit: u/cm2
Time frame: 6 months
Metabolomic profiling of the stool
Change in concentration of metabolites in the stool of AGA vs healthy cohorts.
Time frame: 6 months
Gut and Scalp/Follicle Microbiome Signature Differences at Baseline
Taxonomic and functional composition of the gut and scalp/hair follicle microbiome. Units: relative abundance
Time frame: Baseline
Change in proteomic profile
Change in protein expression levels in scalp swabs samples, and differences between AGA and healthy cohorts.
Time frame: 6 months
Change in Gene Expression Profiles (Transcriptomics)
Evaluation of differentially expressed genes via spatial transcriptomics and single-cell RNA sequencing (scRNA-seq) from scalp biopsy samples comparing AGA participants to healthy controls. Units: Log2 Fold Change (or "Normalized Gene Expression Counts")
Time frame: 6 months
Metabolomic profile in blood/plasma
Change in concentration of metabolites in blood/plasma
Time frame: 6 months
Proteomic profiling of the blood
Change in proteins concentration levels in blood/plasma
Time frame: 6 months
Change in hair diameter distribution
Change from baseline in hair shaft diameter. Unit: µm
Time frame: 6 months
Eyebrow to hairline measurement
The distance from the eyebrow to the hairline is one indicator of the recession of hairline
Time frame: 6 months
Dandruff scoring
The dandruff score ranges from 0 (no dandruff state) to 5 (very important dandruff state) for both adherent and non-adherent dandruffs
Time frame: 6 months
Change in Subject-Reported Hair Density
Evaluation of the volunteer's perceived change in hair density since the start of the study (assessed via self-assessment questionnaire). Scale : improvements range from "worsened significantly" to "improved significantly"
Time frame: 6 months
Measurement of sebum levels
Measure sebum levels on the forehead and scalp
Time frame: 6 months
Gut Microbiome in Oral Minoxidil Treatment Response
Association between gut microbiome composition (metabolomics and metagenomics from stool and blood/plasma) and clinical response to oral minoxidil treatment.
Time frame: 6 months
Change in Follicular Units Distribution
Change from baseline in percentage of single, double, triple... follicular units.
Time frame: 6 months
No study locations are listed for this record.
Plan to share: Yes — Non-identifiable data will be shared with funding/research partners.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Jan 2028, 17 months later.
Of 18 observational studies under Alopecia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 38. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Skin Centre